All The Claims

1. A megestrol nanoparticulate composition comprising:
(a) particles of megestrol, megestrol acetate, or a salt or derivative thereof having an effective average particle size of less than about 2000 nm; and
(b) at least one surface stabilizer.
2. The composition of claim 1, wherein the megestrol, megestrol acetate, or a salt or derivative thereof is selected from the group consisting of a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi-amorphous phase, and mixtures thereof.
3. The composition of claim 1, wherein the effective average particle size of the particles of megestrol, megestrol acetate, or a salt or derivative thereof is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.
4. The composition of claim 1, wherein the composition is formulated:
(a) for administration selected from the group consisting of parental injection, oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, otically, ocular, local, buccal, intracisternal, intraperitoneal, and topical administration;
(b) into a dosage form selected from the group consisting of liquid dispersions, gels, sachets, solutions, aerosols, ointments, tablets, capsules, creams, and mixtures thereof;
(c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or
(d) any combination thereof.
5. The composition of claim 1, wherein the composition further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.
6. The composition of claim 1, wherein:
(a) the megestrol is present in an amount selected from the group consisting of from about 99.5% to about 0.001%, from about 95% to about 0.1%, and from about 90% to about 0.5%, by weight, based on the total combined weight of the megestrol and at least one surface stabilizer, not including other excipients;
(b) the at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999%, from about 5.0% to about 95%, and from about 10% to about 99.5%, by weight, based on the total combined dry weight of the megestrol and at least one surface stabilizer, not including other excipients; or
(c) any combination thereof.
7. The composition of claim 1, comprising at least two surface stabilizers.
8. The composition of claim 1, wherein the surface stabilizer is selected from the group consisting of a nonionic surface stabilizer, an ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, and a zwitterionic surface stabilizer.
9. The composition of claim 1, wherein the at least one surface stabilizer is selected from the group consisting of cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers; poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide; n-decyl \u03b2-D-glucopyranoside; n-decyl \u03b2-D-maltopyranoside; n-dodecyl \u03b2-D-glucopyranoside; n-dodecyl \u03b2-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-\u03b2-D-glucopyranoside; n-heptyl \u03b2-D-thioglucoside; n-hexyl \u03b2-D-glucopyranoside; nonanoyl-N-methylglucamide; n-noyl \u03b2-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-\u03b2-D-glucopyranoside; octyl \u03b2-D-thioglucopyranoside; lysozyme, PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl acetate and vinyl pyrrolidone, a cationic polymer, a cationic biopolymer, a cationic polysaccharide, a cationic cellulosic, a cationic alginate, a cationic nonpolymeric compound, a cationic phospholipid, polymethylmethacrylate trimethylammonium bromide, polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate, hexadecyltrimethyl ammonium bromide, cationic lipids, sulfonium compounds, phosphonium compounds, quarternary ammonium compounds, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride, coconut trimethyl ammonium bromide, coconut methyl dihydroxyethyl ammonium chloride, coconut methyl dihydroxyethyl ammonium bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride bromide, C12-15-dimethyl hydroxyethyl ammonium chloride, C12-15dimethyl hydroxyethyl ammonium chloride bromide, coconut dimethyl hydroxyethyl ammonium chloride, coconut dimethyl hydroxyethyl ammonium bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl dimethyl(ethenoxy)4 ammonium chloride, lauryl dimethyl(ethenoxy)4 ammonium bromide, N-alkyl (C12-18)dimethylbenzyl ammonium chloride, N-alkyl (C14-18)dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C12-14)dimethyl 1-napthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts, dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt, an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C12-14)dimethyl 1-naphthylmethyl ammonium chloride, dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C12 trimethyl ammonium bromides, C15 trimethyl ammonium bromides, C17 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halo genides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride, POLYQUAT 10\u2122, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters, benzalkonium chloride, stearalkonium chloride compounds, cetyl pyridinium bromide, cetyl pyridinium chloride, halide salts of quaternized polyoxyethylalkylamines, MIRAPOL\u2122, ALKAQUAT\u2122, alkyl pyridinium salts; amines, amine salts, amine oxides, imide azolinium salts, protonated quaternary acrylamides, methylated quaternary polymers, lysozyme, and cationic guar.
10. The composition of claim 1, wherein the amount of megestrol is selected from the group consisting of 3 percent by weight, 5 percent by weight, and 9 percent by weight.
11. The composition of claim 1, additionally comprising at least one non-megestrol active agent.
12. The composition of claim 11, wherein the active agent is selected from the group consisting of amino acids, proteins, peptides, nucleotides, anti-obesity drugs, nutraceuticals, dietary supplements, central nervous symptom stimulants, carotenoids, corticosteroids, elastase inhibitors, anti-fungals, alkylxanthine, oncology therapies, anti-emetics, analgesics, opioids, antipyretics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, alpha-adrenergic receptor blocking agents, beta-adrenoceptor blocking agents, blood products, blood substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants, anoretics, sympathomimetics, thyroid agents, vasodilators, vasomodulator, xanthines, Mu receptor antagonists, Kappa receptor antagonists, non-narcotic analgesics, monoamine uptake inhibitors, adenosine regulating agents, cannabinoid derivatives, Substance P antagonists, neurokinin-1 receptor antagonists, and sodium channel blockers.
13. The composition of claim 1, wherein:
(a) upon administration the composition redisperses such that the megestrol particles have a particle size selected from the group consisting of less than about 2 microns, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm;
(b) the composition redisperses in a biorelevant media such that the megestrol particles have a particle size selected from the group consisting of less than about 2 microns, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm; or
(c) any combination thereof.
14. The composition of claim 1, wherein the composition:
(a) does not produce significantly different absorption levels (AUC) when administered under fed as compared to fasting conditions;
(b) does not produce significantly different rates of absorption (Tmax) when administered under fed as compared to fasting conditions;
(c) does not produce a significantly different Cmax when administered under fed as compared to fasting conditions; or
(d) any combination thereof.
15. The composition of claim 1, wherein:
(a) the difference in absorption of the nanoparticulate megestrol composition, when administered in the fed versus the fasted state, is selected from the group consisting of less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, and less than about 3%;
(b) the difference in the Tmax for the nanoparticulate megestrol composition, when administered in the fed versus the fasted state, is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, and less than about 3%;
(c) the difference in Cmax for the nanoparticulate megestrol composition, when administered in the fed versus the fasted state, is less than about 600%, less than about 575%, less than about 550%, less than about 525%, less than about 500%, less than about 475%, less than about 450%, less than about 425%, less than about 400%, less than about 375%, less than about 350%, less than about 325%, less than about 300%, less than about 275%, less than about 250%, less than about 225%, less than about 200%, less than about 175%, less than about 150%, less than about 125%, less than about 100%, less than about 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%; or
(d) any combination thereof.
16. The composition of claim 1, wherein following administration the composition has a Tmax selected from the group consisting of less than about 5 hours, less than about 4.5 hours, less than about 4 hours, less than about 3.5 hours, less than about 3 hours, less than about 2.75 hours, less than about 2.5 hours, less than about 2.25 hours, less than about 2 hours, less than about 1.75 hours, less than about 1.5 hours, less than about 1.25 hours, less than about 1.0 hours, less than about 50 minutes, less than about 40 minutes, less than about 30 minutes, less than about 25 minutes, less than about 20 minutes, less than about 15 minutes, and less than about 10 minutes.
17. The composition of claim 1, wherein:
(a) the Tmax of megestrol or a salt or derivative thereof, when assayed in the plasma of a mammalian subject following administration, is less than the Tmax for a non-nanoparticulate composition of the same megestrol, administered at the same dosage;
(b) the Cmax of megestrol or a salt or derivative thereof, when assayed in the plasma of a mammalian subject following administration, is greater than the Cmax for a non-nanoparticulate composition of the same megestrol, administered at the same dosage;
(c) the AUC of megestrol or a salt or derivative thereof, when assayed in the plasma of a mammalian subject following administration, is greater than the AUC for a non-nanoparticulate composition of the same megestrol, administered at the same dosage; or
(d) any combination thereof.
18. The composition of claim 1, wherein in comparative pharmacokinetic testing with a standard commercial non-nanoparticulate composition of megestrol, administered at the same dosage, the nanoparticulate composition exhibits a Cmax selected from the group consisting of greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 100%, greater than about 110%, greater than about 120%, greater than about 130%, greater than about 140%, greater than about 150%, greater than about 200%, greater than about 500% and greater than about 800% than the Cmax exhibited by the non-nanoparticulate composition of megestrol.
19. The composition of claim 1, wherein the therapeutically effective amount of the megestrol is selected from the group consisting of \u2159, \u2155, \xbc, \u2153rd, or \xbd of the therapeutically effective amount of a standard commercial megestrol formulation.
20. The composition of claim 1, wherein the composition is in a liquid oral dosage form, and:
(a) the viscosity of the composition is selected from the group consisting of less than about 1200, less than about 1175, less than about 1150, less than about 1125, less than about 1100, less than about 150, and less than about 125 of the viscosity of a standard commercial liquid oral megestrol formulation at about the same concentration per ml of megestrol;
(b) the viscosity of the composition is selected from the group consisting of from about 175 mPa s to about 1 mPa s, from about 150 mPa s to about 1 mPa, from about 125 mPa s to about 1 mPa s, from about 100 mPa s to about 1 mPa s, from about 75 mPa s to about 1 mPa s, from about 50 mPa s to about 1 mPa s, from about 25 mPa s to about 1 mPa s, from about 15 mPa s to about 1 mPa s, and from about 5 mPa s to about 1 mPa s; or
(c) any combination thereof.
21. A method of making a nanoparticulate megestrol composition comprising contacting megestrol particles with at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate megestrol composition having an effective average particle size of less than about 2000 nm.
22. The method of claim 21, wherein said contacting comprising grinding, wet grinding, homogenization, precipitation, freezing, template emulsion, or a combination thereof.
23. The method of claim 21, wherein the effective average particle size of the nanoparticulate megestrol particles is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.
24. A method of treating a subject in need with a nanoparticulate megestrol formulation comprising administering to the subject an effective amount of a megestrol composition comprising:
(a) particles of megestrol, megestrol acetate, or a salt or derivative thereof having an effective average particle size of less than about 2000 nm; and
(b) at least one surface stabilizer,
25. The method of claim 24, wherein the condition to be treated is selected from the group consisting of neoplastic diseases, breast cancer, endometrial cancer, uterine cancer, cervical cancer, prostate cancer, renal cancer, hormone replacement therapy in post-menopausal women, endometriosis, hirsutism, dysmenorrhea, uterine bleeding, HIV wasting, cancer wasting, cachexia, anorexia, castration, and oral contraception.
26. The method of claim 24, wherein the condition to be treated is anorexia andor cachexia associated with Human Immunodeficiency Virus (HIV) infection andor Acquired Immune Deficiency Syndrome (AIDS).
27. The method of claim 24, wherein the megestrol formulation is administered in the form of an oral suspension.
28. The method of claim 24, wherein a maximum blood plasma concentration of megestrol acetate, or a salt or derivative thereof:
(a) is attained in about 1 hour or less after administration of the nanoparticulate megestrol formulation in fasting subjects;
(b) of at least about 700 ngml is obtained;
(c) is at least about 700 ngml and is attained in less than 5 hours after administration of the nanoparticulate megestrol formulation;
(d) is at least about 400 ngml and is attained in less than 5 hours after administration of the nanoparticulate megestrol formulation; or
(e) any combination thereof.
29. The method of claim 24, wherein the megestrol formulation is administered in an amount providing:
(a) from about 1 mgday to about 1000 mgday of megestrol;
(b) from about 40 mgday to about 800 mgday of megestrol;
(c) from about 500 mgday to about 700 mgday of megestrol;
(d) about 575 mgday;
(e) about 625 mgday; or
(f) about 675 mgday.
30. The method of claim 24, wherein the effective average particle size of the particles of megestrol, megestrol acetate, or a salt or derivative thereof is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A lighting device, comprising:
at least one lamp arranged to generate first light (11); and
at least one OLED arranged to generate second light and to transmit at least part of the first light,
wherein the at least one lamp is arranged to generate the first light into a first beam and the at least one OLED is arranged to generate the second light into a second beam, first and second beams leaving the lighting device at different angles.
2. The lighting device according to claim 1, wherein the at least one lamp is selected from the group consisting of: filament lamps, fluorescent lamps, luminescent tubes, halogen lamps, low-pressure gas discharge lamps, high-pressure gas discharge lamps, LEDs and OLEDs.
3. The lighting device according to claim 1, wherein the at least one OLED is selected from the group of PolyLEDs and small-molecule OLEDs.
4. The lighting device according to claim 1, wherein the at least one lamp is arranged to illuminate at least part of the at least one OLED with at least 40% of the total flux of the first light.
5. The lighting device according to claim 1, further comprising a beam manipulator comprising at least one reflector andor at least one collimator and arranged to manipulate at least part of the first light and illuminate at least part of the at least one OLED with manipulated light.
6-7. (canceled)
8. The lighting device according to claim 1, further comprising a window pane comprising the at least one OLED.
9. The lighting device according to claim 8, wherein the window pane has at least one edge tilted at angle \u03b1 relative to a normal to the at least one OLED, wherein 0\xb0<\u03b1<90\xb0 or 90\xb0<\u03b1<180\xb0.
10. The lighting device according to claim 1, wherein, relative to a normal to the at least one OLED, the first beam has a cut-off angle \u03b21 and the second beam has a cut-off angle \u03b32 and wherein \u03b32\u2267\u03b21.
11. The lighting device according to claim 10, wherein, at angles\u2267\u03b21, the luminance of the lighting device due to the first beam and, at angles\u2267\u03b32, the luminance of the lighting device due to the second beam are independently \u22661000 cdm2.
12-15. (canceled)
16. The lighting device according to claim 10, wherein 0\xb0<\u03b21\u226665\xb0.
17. The lighting device (1) according to claim 10, wherein 2\xb0<\u03b32<65\xb0, 0\xb0<\u03b21<30\xb0, and \u03b32>\u03b21.
18-19. (canceled)
20. The lighting device (1) according to claim 10, wherein at least the first beam has an asymmetric light distribution.
21. The lighting device (1) according to claim 1, wherein the at least one OLED has a transmission of at least 70% for visible light of the at least one lamp.
22. (canceled)

1. A method in a client-server environment, to manage a configuration of resources on at least one client system, the method on a client system comprising:
receiving one or more predetermined events along with one or more local run-time environmental conditions along with one or more user selectable settings; and
running a monitoring agent on the client system to detect when one or more predetermined events occur then determining if the one or more local run-time environmental conditions are met and if the conditions are met then automatically applying at least one of the one or more selectable configuration settings on the client system;
wherein at least one of the predetermined events, the settings and the environmental conditions are previously set graphically using a graphical user interface with one or more user selectable selections therein.
2. The method according to claim 1, wherein the running a monitoring agent on the client system to determine if the predetermined event occurs includes determining if at least one of a system start-up, a logon, a period of user inactivity, a network connection, a process startstop, an application startstop, a virus detection, a hardware change, a message, a logoff, and a system shutdown.
3. The method according to claim 2, wherein the running a monitoring agent on the client system to determine if the predetermined event occurs includes determining if at least one of a period of user inactivity occurs within a predetermined time window.
4. The method according to claim 1, wherein the running a monitoring agent on the client system includes applying at least one the one or more selectable configuration settings on the client system by launching at least one of an additional application and script, to make a change to the one or more configuration settings.
5. The method according to claim 1, wherein the running a monitoring agent on the client system includes automatically applying at least one of the one or more selectable configuration settings on the client system from the group of configuration settings consisting of security policies, drive mappings, startup applications, registry settings, printer deployment, Internet settings, desktop shortcuts, proxy server access, application paths, Microsoft Office paths, Microsoft OutlookExchange mail profiles, profiles, service packs, anti-virus updates, and other policies.
6. The method according to claim 5, wherein the running a monitoring agent on the client system for automatically applying at least one of the one or more selectable configuration settings on the client system includes running a monitoring agent to determine at least one of an installation and an execution of an unauthorized program and when one of the installation and the execution of the unauthorized program occurs then performing one or more of the following:
disabling a process running the unauthorized program;
sending an e-mail notification;
locking access to the client system.
7. The method according to claim 1, wherein the running a monitoring agent on the client system for automatically applying at least one of the one or more selectable configuration settings on the client system includes one or more selectable configuration settings for an operating system running on the client system.
8. The method according to claim 1, wherein the running a monitoring agent on the client system for automatically applying at least one of the one or more selectable configuration settings on the client system includes one or more selectable configuration settings for an application running on the client system.
9. The method according to claim 1, wherein the receiving one or more predetermined events along with one or more local run-time environmental conditions along with one or more user selectable settings includes receiving at least one of the predetermined events, environmental conditions and user selectable settings from a group of computer readable medium consisting of networks, diskettes, CDs, DVDs, and non-volatile memory.
10. The method according to claim 1, wherein the running a monitoring agent on the client system for automatically applying at least one of the one or more selectable configuration settings on the client system includes one or more selectable configuration settings for executing a custom application script so as to cause the custom application program to alter at least one of the configuration settings.
11. The method according to claim 1, wherein the receiving one or more predetermined events along with one or more local run-time environmental conditions includes one or more environmental conditions of Domain, Site, Organization Unit Computer, Organization Unit User, Group Membership, Primary Group, User Name, TCPIP address, Host Address, Computer Name, MAC Address, Terminal Services Application Name, Terminal Services Initial Program, Terminal Services Client Name, Terminal Services Session Name, Terminal Services Client TCPIP Address, operating system, LAN connection, Dial-up connection, Desktop machine, Portables machine, Terminal Services Client, Member Server, and Domain Controller.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A precision motion transducer, comprising:
a first elastic body with a first modulus of elasticity, provided with a first end and a second end;
a second elastic body with a second modulus of elasticity which is larger than the first modulus of elasticity, the second elastic body being provided with a fixed portion and a free portion, the free portion being attached to the second end of the first elastic body;
a fixing means for fixing the fixed portion of the second elastic body to a base;
a motion input means for inputting motion inputs to the first end of the first elastic body; and
a motion output means provided at a location where the first elastic body and the second elastic body are connected with each other for outputting motion outputs which are converted from the motion inputs according to an elasticity ratio between the modulus of elasticity of the first elastic body and the modulus of elasticity of the second elastic body, wherein the free portion of the second elastic body is directly attached to the second end of the first elastic body.
2. The precision motion transducer of claim 1, wherein the second elastic body is an ends-fixed beam, wherein a central portion of the ends-fixed beam is the free portion, and two end portions of the ends-fixed beam are the fixed portions, the second modulus of elasticity referring to a modulus of elasticity of the central portion with respect to the two end portions.
3. The precision motion transducer of claim 1, wherein the first elastic body is a spring.
4. The precision motion transducer of claim 1, wherein the motion input andor the motion output are linear motions.
5. The precision motion transducer of claim 1, wherein the motion input means includes a micrometer.
6. The precision motion transducer of claim 1, wherein the motion input means includes a motor.
7. The precision motion transducer of claim 1, wherein the motion input means includes a piezo-actuator.
8. The precision motion transducer of claim 1, wherein the motion input means includes a voice coil.
9. The precision motion transducer of claim 1, wherein the motion input means includes a hydraulic linear actuator.
10. The precision motion transducer of claim 1, wherein the motion input means includes an air linear actuator.
11. The precision motion transducer of claim 1, further comprising: a motion output feedback device for monitoring the motion output and transmitting a feedback signal corresponding to the motion output.